Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2

نویسندگان

  • A. Reghan Foley
  • Manoj P. Menezes
  • Amelie Pandraud
  • Michael A. Gonzalez
  • Ahmad Al-Odaib
  • Alexander J. Abrams
  • Kumiko Sugano
  • Atsushi Yonezawa
  • Adnan Y. Manzur
  • Joshua Burns
  • Imelda Hughes
  • B. Gary McCullagh
  • Heinz Jungbluth
  • Ming J. Lim
  • Jean-Pierre Lin
  • Andre Megarbane
  • J. Andoni Urtizberea
  • Ayaz H. Shah
  • Jayne Antony
  • Richard Webster
  • Alexander Broomfield
  • Joanne Ng
  • Ann A. Mathew
  • James J. O’Byrne
  • Eva Forman
  • Mariacristina Scoto
  • Manish Prasad
  • Katherine O’Brien
  • Simon Olpin
  • Marcus Oppenheim
  • Iain Hargreaves
  • John M. Land
  • Min X. Wang
  • Kevin Carpenter
  • Rita Horvath
  • Volker Straub
  • Monkol Lek
  • Wendy Gold
  • Michael O. Farrell
  • Sebastian Brandner
  • Rahul Phadke
  • Kazuo Matsubara
  • Michael L. McGarvey
  • Steven S. Scherer
  • Peter S. Baxter
  • Mary D. King
  • Peter Clayton
  • Shamima Rahman
  • Mary M. Reilly
  • Robert A. Ouvrier
  • John Christodoulou
  • Stephan Züchner
  • Francesco Muntoni
  • Henry Houlden
چکیده

Childhood onset motor neuron diseases or neuronopathies are a clinically heterogeneous group of disorders. A particularly severe subgroup first described in 1894, and subsequently called Brown-Vialetto-Van Laere syndrome, is characterized by progressive pontobulbar palsy, sensorineural hearing loss and respiratory insufficiency. There has been no treatment for this progressive neurodegenerative disorder, which leads to respiratory failure and usually death during childhood. We recently reported the identification of SLC52A2, encoding riboflavin transporter RFVT2, as a new causative gene for Brown-Vialetto-Van Laere syndrome. We used both exome and Sanger sequencing to identify SLC52A2 mutations in patients presenting with cranial neuropathies and sensorimotor neuropathy with or without respiratory insufficiency. We undertook clinical, neurophysiological and biochemical characterization of patients with mutations in SLC52A2, functionally analysed the most prevalent mutations and initiated a regimen of high-dose oral riboflavin. We identified 18 patients from 13 families with compound heterozygous or homozygous mutations in SLC52A2. Affected individuals share a core phenotype of rapidly progressive axonal sensorimotor neuropathy (manifesting with sensory ataxia, severe weakness of the upper limbs and axial muscles with distinctly preserved strength of the lower limbs), hearing loss, optic atrophy and respiratory insufficiency. We demonstrate that SLC52A2 mutations cause reduced riboflavin uptake and reduced riboflavin transporter protein expression, and we report the response to high-dose oral riboflavin therapy in patients with SLC52A2 mutations, including significant and sustained clinical and biochemical improvements in two patients and preliminary clinical response data in 13 patients with associated biochemical improvements in 10 patients. The clinical and biochemical responses of this SLC52A2-specific cohort suggest that riboflavin supplementation can ameliorate the progression of this neurodegenerative condition, particularly when initiated soon after the onset of symptoms.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Late-onset and acute presentation of Brown-Vialetto-Van Laere syndrome in a Brazilian family

Riboflavin transporter deficiency (formerly known as Brown-Vialetto-Van Laere [BVVL] or Fazio-Londe syndrome) is a neurodegenerative disorder characterized by progressive bulbar palsy with sensorineural deafness or bulbar hereditary neuropathy. It is caused by mutations in the riboflavin transporter genes SLC52A2 (RFVT2) or SLC52A3 (RFVT3). It is a rare syndrome with approximately 70 cases repo...

متن کامل

Genome-wide RNA-seq of iPSC-derived motor neurons indicates selective cytoskeletal perturbation in Brown–Vialetto disease that is partially rescued by riboflavin

Riboflavin is essential in numerous cellular oxidation/reduction reactions but is not synthesized by mammalian cells. Riboflavin absorption occurs through the human riboflavin transporters RFVT1 and RFVT3 in the intestine and RFVT2 in the brain. Mutations in these genes are causative for the Brown-Vialetto-Van Laere (BVVL), childhood-onset syndrome characterized by a variety of cranial nerve pa...

متن کامل

Riboflavin uptake transporter Slc52a2 (RFVT2) is upregulated in the mouse mammary gland during lactation.

While it is well recognized that riboflavin accumulates in breast milk as an essential vitamin for neonates, transport mechanisms for its milk excretion are not well characterized. The multidrug efflux transporter ABCG2 in the apical membrane of milk-producing mammary epithelial cells (MECs) is involved with riboflavin excretion. However, it is not clear whether MECs possess other riboflavin tr...

متن کامل

Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease.

Brown-Vialetto-Van Laere syndrome was first described in 1894 as a rare neurodegenerative disorder characterized by progressive sensorineural deafness in combination with childhood amyotrophic lateral sclerosis. Mutations in the gene, SLC52A3 (formerly C20orf54), one of three known riboflavin transporter genes, have recently been shown to underlie a number of severe cases of Brown-Vialetto-Van ...

متن کامل

A Case of Brown-Vialetto-Van Laere Syndrome Due To a Novel Mutation in SLC52A3 Gene

Brown-Vialetto-Van Laere syndrome is a rare disorder characterized by motor, sensory, and cranial neuronopathies, associated with mutations in SLC52A2 and SLC52A3 genes that code for human riboflavin transporters RFVT2 and RFVT3, respectively. The authors describe the clinical course of a 6-year-old girl with Brown-Vialetto-Van Laere syndrome and a novel homozygous mutation c.1156T>C in the SLC...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 137  شماره 

صفحات  -

تاریخ انتشار 2014